Andrew L. Pecora, MD

Complementary! Sounds good, how could it hurt? When applied in cancer therapy, however, what sounds good may not always be good for patients.

In 2011, the FDA reported 232 cancer therapies to be in limited supply. As a result, many patients have had therapies delayed or discontinued, and in some cases, patients have been left without access to appropriate alternatives.

Much has been made of the difficulties companies, investigators, and patient advocates have in providing access to novel therapies.

The FDA has broad authority to regulate food safety, as well as the safety, efficacy, and utilization of drugs and medical devices.

A look at tweaking the corruptive influence of the virus information code to selectively corrupt cancer cells while sparing (normal) cells that do not have a specific cancer phenotype.

In vitro cell manipulation has unleashed the therapeutic potential of human cells.

In the context of caring for cancer patients, all physicians and nurses trained in oncology receive education in quality-of-life issues; however, prolonging quantity of life remains our ultimate goal.

Oncologists need to prepare for a new era in which rapidly advancing genetic technology will change the way cancer is treated.

Recently, significant attention has been focused on dark energy, despite our inability to directly detect it, because it represents 72% of everything in the universe

The explosion of knowledge emanating from laboratories and clinics across the globe is steadily clearing the "haze" that shrouds the molecular basis of malignant cell transformation, growth, and spread